|
 |
||||||||
 |
Commercialization Strategy Currently, we intend to build a commercial capability in the U.S. focused on Exelbine™ (vinorelbine injectable emulsion), as well as other products that we may develop or acquire. We believe we can achieve our strategic goals by through a targeted approach that combines contracting with oncology group purchasing organizations to help create awareness of our products and deploying a specialized, experienced sales force to call on physicians and nurses at community oncology practices and other organizations with defined characteristics, such as high vinorelbine use. In preparing for the potential commercial launch of Exelbine, we expect to develop or acquire certain internal marketing, distribution and sales capabilities and associated regulatory compliance capabilities, as well as contract with third parties to supplement and enhance our internal capabilities. A key component to our commercial strategy in the U.S. for Exelbine is to obtain a unique Healthcare Common Procedure Coding System, or HCPCS, product code that is distinct from the code for Navelbine® and its generic equivalents. If our products are provided unique HCPCS product codes, they will be reimbursed based on their own sales prices, without including sales prices of the applicable reference product or its generic competition. We believe this will allow for appropriate pricing for our products relative to competitive products. |
